Attention deficit and hyperactivity disorder, methylphenidate, and epilepsy.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 15613514.
- Also identified by PMC identifier 1720074.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Attention deficit hyperactivity disorder (ADHD) is characterised by inattention, impulsivity, and hyperactivity. The DSM-IV diagnosis of ADHD requires the presence of six of nine items or features that must have been present for at least six months, to have had an onset before 7 years of age, and to have resulted in significant distress or impairment.1 In the general population, the prevalence of ADHD is approximately 5%.2 There is a high co-morbidity of epilepsy and attentional and behavioural problems,3,4 including ADHD, and it has been estimated that at least 20% of patients with epilepsy may present with features of ADHD.5.
Medical subject headings
- Attention Deficit Disorder with Hyperactivity
- Central Nervous System Stimulants
- Epilepsy
- Methylphenidate